Satiety signals and obesity

Current Opinion in Gastroenterology

Volumn 29, Issue 2, 2013, Pages 222-227

  Hellström, Per M ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

bariatric surgery; GLP 1; obesity surgery; PYY; weight control

Indexed keywords

AGOUTI RELATED PROTEIN; CHOLECYSTOKININ; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; GHRELIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; LIRAGLUTIDE; MELANOCORTIN 3 RECEPTOR; MELANOCORTIN 4 RECEPTOR; MOTILIN; NEUROPEPTIDE Y; OXYNTOMODULIN; PANCREAS POLYPEPTIDE; PEPTIDE YY; PEPTIDE YY [3-36]; PREPROGLUCAGON; TEDUGLUTIDE;

APPETITE; ARCUATE NUCLEUS; BARIATRIC SURGERY; BILIOPANCREATIC BYPASS; BODY WEIGHT; BRAIN STEM; CALORIC INTAKE; DRUG SAFETY; ENERGY EXPENDITURE; FOOD INTAKE; GASTRIC SLEEVE; GASTROINTESTINAL TRACT; GLUCAGON BLOOD LEVEL; GLUCONEOGENESIS; GLYCOGENOLYSIS; HORMONE RELEASE; HUMAN; HUNGER; HYPOTHALAMUS; INTESTINE MOTILITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OVERNUTRITION; PROTEIN EXPRESSION; REVIEW; SATIETY; SIGNAL TRANSDUCTION; SOLITARY TRACT NUCLEUS; STOMACH BYPASS; STOMACH EMPTYING; WEIGHT REDUCTION;

BARIATRIC SURGERY; DIABETES MELLITUS, TYPE 2; GASTROINTESTINAL HORMONES; HUMANS; HUNGER; OBESITY; SATIATION; SIGNAL TRANSDUCTION;

EID: 84873410160     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32835d9ff8     Document Type: Review

References (53)

1. Cummings DE, Frayo RS, Marmonier C, et al. Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time- and foodrelated cues. Am J Physiol 2004; 287:E297-E304.
2. Druce MR, Wren AM, Park AJ, et al. Ghrelin increases food intake in obese as well as lean subjects. Int J Obes (Lond) 2005; 29:1130-1136.
3. Sato N, Ogino Y, Mashiko S, Ando M. Modulation of neuropeptide Y receptors for the treatment of obesity. Expert Opin Ther Pat 2009; 19:1401-1415.
4. Fu LY, van den Pol AN. Agouti-related peptide and MC3/4 receptor agonists both inhibit excitatory hypothalamic ventromedial nucleus neurons. J Neurosci 2008; 28:5433-5449.
5. Tolle V, Low MJ. In vivo evidence for inverse agonismof Agouti-related peptide in the central nervous system of proopiomelanocortin-deficient mice. Diabetes 2008; 57:86-94.
6. Ang DC, Nicolai H, Vos R, et al. Hunger scores correlate with the occurrence of pharmacologically induced gastric phase 3 in man. Gastroenterology 2008; 134 (Suppl. 1):A-285.
7. Chen CY, Tsai CY. Ghrelin and motilin in the gastrointestinal system. Curr Pharm Des 2012; 18:4755-4765.
8. Kral JG, Na? slund E. Surgical treatment of obesity. Nat Clin Pract Endocrinol Metab 2007; 3:574-583.
9. Horner KM, Byrne NM, Cleghorn GJ, et al. The effects of weight loss strategies on gastric emptying and appetite control. Obes Rev 2011; 12:935-951.
10. Miras AD, le Roux CW. Bariatric surgery and taste: novel mechanisms of weight loss. Curr Opin Gastroenterol 2010; 26:140-145.
11. Hedberg J, Sundbom M. Superior weight loss and lower HbA1c 3 years after duodenal switch compared with Roux-en-Y gastric bypass Y a randomized controlled trial. Surg Obes Relat Dis 2012; 8:338-343.
12. Sanger GJ, Hellstro?m PM, Na?slund E. The hungry stomach: physiology, disease, and drug development opportunities. Front Pharmacol 2010; 1:117-126; doi: 10.3389/fphar.2010.00145.
13. Herrmann C, Go? ke R, Richter G, et al. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995; 56:117-126.
14. Rocca AS, Brubaker PL. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 1999; 140:1687-1694.
15. Chu ZL, Carroll C, Alfonso J, et al. A role for intestinal endocrine cellexpressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology 2008; 149:2038-2047.
16. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet 1987; 2:1300-1304.
17. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3:153-165.
18. Chaudhri O, Small C, Bloom S. Gastrointestinal hormones regulating appetite. Philos Trans R Soc Lond B Biol Sci 2006; 361:1187-1209.
19. Parkinson JR, Chaudhri OB, Kuo YT, et al. Differential patterns of neuronal activation in the brainstem and hypothalamus following peripheral injection of GLP-1, oxyntomodulin and lithium chloride in mice detected by manganeseenhanced magnetic resonance imaging (MEMRI). Neuroimage 2009; 44: 1022-1031.
20. Shyangdan DS, Royle P, Clar C, et al. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011:CD006423.
21. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012; 36:843-854.
22. Pencek R, Blickensderfer A, Li Y, et al. Exenatide twice daily: Analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Postgrad Med 2012; 124:21-32.
23. Gutniak MK, Juntti-Berggren L, Hellstro?m PM, et al. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas. Diabetes Care 1996; 19:857-863.
24. Baggio LL, Huang Q, Brown TJ, Drucker DJ. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 2004; 127:546-558.
25. Schjoldager B, Mortensen PE, Myhre J, et al. Oxyntomodulin from distal gut. Role in regulation of gastric and pancreatic functions. Dig Dis Sci 1989; 34:1411-1419.
26. Wynne K, Park AJ, Small CJ, et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: A randomised controlled trial. Int J Obes (Lond) 2006; 30:1729-1736.
27. Chaudhri OB, Parkinson JR, Kuo YT, et al. Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging. Biochem Biophys Res Commun 2006; 350:298-306.
28. Dakin CL, Small CJ, Batterham RL, et al. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 2004; 145:2687-2695.
29. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, et al. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985; 89:1070-1077.
30. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349:941-948.
31. Batterham RL, Heffron H, Kapoor S, et al. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab 2006; 4:223-233.
32. Vrang N, Madsen AN, Tang-Christensen M, et al. PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity. Am J Physiol 2006; 291:R367-R375.
33. Degen L, Oesch S, Casanova M, et al. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 2005; 129:1430-1436.
34. Sloth B, Holst JJ, Flint A, et al. Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am J Physiol 2007; 292:E1062-E1068.
35. Witte AB, Gryba?ck P, Holst JJ, et al. Differential effect of PYY1-36 and PYY3-36 on gastric emptying in man. Regul Pept 2009; 158: 57-62.
36. Na?slund E, Bogefors J, Skogar S, et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 1999; 277:R910-R916.
37. Buffa R, Solcia E, Go VL. Immunohistochemical identification of the cholecystokinin cell in the intestinal mucosa. Gastroenterology 1976; 70:528-532.
38. Blevins JE, Stanley BG, Reidelberger RD. Brain regions where cholecystokinin suppresses feeding in rats. Brain Res 2000; 860:1-10.
39. Crawley JN, Beinfeld MC. Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 1983; 302:703-706.
40. Schmidt PT, Na? slund E, Gryba?ck P, et al. Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety. Regul Pept 2003; 116:21-25.
41. Tang-Christensen M, Larsen PJ, Thulesen J, et al. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med 2000; 6:802-807.
42. Jeppesen PB, Pertkiewicz M, Messing B, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology 2012; 143:1473-1481. pii: S0016-5085(12)01316-9. doi: 10.1053/j.gastro.2012.09.007. [Epub ahead of print].
43. Jeppesen PB, Gilroy R, Pertkiewicz M, et al. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut 2011; 60:902-914.
44. Schmidt PT, Na?slund E, Gryba?ck P, et al. A role for pancreatic polypeptide in the regulation of gastric emptying and short-term metabolic control. J Clin Endocrinol Metab 2005; 90:5241-5246.
45. Woods SC, Lutz TA, Geary N, Langhans W. Pancreatic signals controlling food intake; insulin, glucagon and amylin. Philos Trans R Soc Lond B Biol Sci 2006; 361:1219-1235.
46. Habegger KM, Heppner KM, Geary N, et al. The metabolic actions of glucagon revisited. Nat Rev Endocrinol 2010; 6:689-697.
47. Pocai A, Carrington PE, Adams JR, et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 2009; 58:2258-2266.
48. Day JW, Ottaway N, Patterson JT, et al. A new glucagon and GLP-1 coagonist eliminates obesity in rodents. Nat Chem Biol 2009; 5:749-757.
49. Naslund E, Gryba?ck P, Backman L, et al. Distal small bowel hormones: correlation with fasting antroduodenal motility and gastric emptying. Dig Dis Sci 1998; 43:945-952.
50. Le Roux CW, Batterham RL, Aylwin SJ, et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 2006; 147:3-8.
51. Holdstock C, Zethelius B, Sundbom M, et al. Postprandial changes in gut regulatory peptides in gastric bypass patients. Int J Obes (Lond) 2008; 32:1640-1646.
52. Falkén Y, Hellstro?m PM, Holst JJ, Na?slund E. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: Role of gut peptides. J Clin Endocrinol Metab 2011; 96:2227-2235.
53. Hedberg J, Hedenstrom H, Karlsson FA, et al. Gastric emptying and postprandial PYY response after biliopancreatic diversion with duodenal switch. Obes Surg 2011; 21:609-615.